Real-world tobacco cessation practice in China: findings from the prospective, nationwide multicenter China National Tobacco Cessation Cohort Study (CNTCCS)

被引:7
作者
Liu, Zhao [1 ,2 ,3 ,4 ,5 ]
Qin, Rui [1 ,2 ,3 ,4 ,5 ,6 ]
Hu, Xue-Jun [7 ]
Liu, Li-Jun [8 ]
Xu, Su-Qin [9 ]
Shi, Guo-Chao [10 ]
Zhou, Hong [11 ]
Bai, Jing [12 ]
Zhang, Chun-Mei [13 ]
Qi, Yong [14 ]
Zhou, Wei [15 ]
Lan, Shu-Hua [16 ]
Tong, Jin [17 ]
Su, Tong-Sheng [18 ]
Wang, Qiang [19 ]
Yang, Xin-Yan [20 ]
Sun, De-Jun [21 ]
Zhu, Li-Ming [22 ]
Chen, Xiao-Yang [23 ]
Chen, Hong [24 ]
Xie, Yu-Peng [25 ]
Xiao, Zhi-Hua [26 ]
Chen, Yan-Bin [27 ]
Zhao, Bo [28 ]
Wu, Qiu-Ge [29 ]
Chen, Wen-Li [30 ]
Li, Dong-Yan [31 ]
Liu, Hongbo [28 ]
Cheng, An-Qi [1 ,2 ,3 ,4 ,5 ]
Cui, Zi-Yang [32 ]
Zhao, Liang [1 ,2 ,3 ,4 ,5 ]
Li, Jin-Xuan [1 ,2 ,3 ,4 ,5 ,33 ]
Wei, Xiao-Wen [1 ,2 ,3 ,4 ,5 ,33 ]
Zhou, Xin-Mei [1 ,2 ,3 ,4 ,5 ]
Su, Zheng [1 ,2 ,3 ,4 ,5 ]
Chung, Kian Fan [34 ,35 ]
Chen, Zheng-Ming [36 ]
Xiao, Dan [1 ,2 ,3 ,4 ,5 ,6 ,33 ,37 ]
Wang, Chen [2 ,3 ,4 ,5 ,37 ]
机构
[1] China Japan Friendship Hosp, Ctr Resp Med, Dept Tobacco Control & Prevent Resp Dis, Beijing, Peoples R China
[2] WHO Collaborating Ctr Tobacco Cessat & Resp Dis P, Beijing, Peoples R China
[3] China Natl Ctr Resp Med, Beijing, Peoples R China
[4] China Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China
[5] Chinese Acad Med Sci & Peking Union Med Coll, Inst Resp Med, Beijing, Peoples R China
[6] Peking Union Med Coll, Grad Sch, Beijing, Peoples R China
[7] China Med Univ, Hosp 1, Dept Resp & Crit Care Med, Shenyang, Liaoning, Peoples R China
[8] Baiyin First Peoples Hosp Gansu Prov, Dept Resp & Crit Care Med, Baiyin, Gansu, Peoples R China
[9] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pulm & Crit Care Med, Wuhan, Hubei, Peoples R China
[10] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Resp & Crit Care Med, Sch Med, Shanghai, Peoples R China
[11] Harbin Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, Harbin, Heilongjiang, Peoples R China
[12] Guangxi Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, Nanning, Guangxi, Peoples R China
[13] Capital Med Univ, Beijing Luhe Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China
[14] Henan Prov Peoples Hosp, Dept Pulm & Crit Care Med, Zhengzhou, Henan, Peoples R China
[15] Beijing Hosp, Dept Pulm & Crit Care Med, Beijing, Peoples R China
[16] Fujian Univ Tradit Chinese Med, Dept Pulm & Crit Care Med, Nanping Peoples Hosp, Nanping, Fujian, Peoples R China
[17] Chongqing Med Univ, Affiliated Hosp 2, Dept Resp & Crit Care Med, Chongqing, Peoples R China
[18] Shaanxi Hosp Tradit Chinese Med, Dept Acupuncture & Moxibust 3, Xian, Shaanxi, Peoples R China
[19] Qingdao Univ, Dept Resp & Crit Care Med, Affiliated Hosp, Qingdao, Shandong, Peoples R China
[20] Guangzhou Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, Guangzhou, Guangdong, Peoples R China
[21] Peoples Hosp Inner Mongolia Autonomous Reg, Dept Resp & Crit Care Med, Hohhot, Inner Mongolia, Peoples R China
[22] Hunan Normal Univ, Hunan Prov Peoples Hosp, Dept Resp & Crit Care Med, Affiliated Hosp 1, Changsha, Hunan, Peoples R China
[23] Fujian Med Univ, Affiliated Hosp 2, Dept Pulm & Crit Care Med, Quanzhou, Fujian, Peoples R China
[24] Chongqing Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, Chongqing, Peoples R China
[25] Wenzhou Med Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, Wenzhou, Zhejiang, Peoples R China
[26] Third Peoples Hosp Datong City, Dept Resp & Crit Care Med, Datong, Shanxi, Peoples R China
[27] Soochow Univ, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Suzhou, Jiangsu, Peoples R China
[28] China Med Univ, Shengjing Hosp, Dept Pulm & Crit Care Med, Shenyang, Liaoning, Peoples R China
[29] Zhengzhou Univ, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Zhengzhou, Henan, Peoples R China
[30] Chengde Med Coll, Affiliated Hosp, Dept Resp & Crit Care Med, Chengde, Hebei, Peoples R China
[31] Shanxi Med Univ, Hosp 1, Dept Pulm & Crit Care Med, Taiyuan, Shanxi, Peoples R China
[32] Capital Med Univ, Beijing Shijitan Hosp, Dept Geriatr Med, Beijing, Peoples R China
[33] Capital Med Univ, China Japan Friendship Sch Clin Med, Beijing, Peoples R China
[34] Imperial Coll London, Natl Heart & Lung Inst, London, England
[35] Royal Brompton & Harefield NHS Trust, London, England
[36] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England
[37] China Japan Friendship Hosp, Ctr Resp Med, Dept Pulm & Crit Care Med, Beijing, Peoples R China
来源
LANCET REGIONAL HEALTH-WESTERN PACIFIC | 2023年 / 39卷
基金
国家重点研发计划;
关键词
Smoking; Smoking cessation; Cohort study; China National Tobacco Cessation Cohort Study (CNTCCS); NICOTINE REPLACEMENT THERAPY; SMOKING-CESSATION; EFFICACY; INTERVENTIONS; VARENICLINE; MORTALITY;
D O I
10.1016/j.lanwpc.2023.100826
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Tobacco cessation is proven to be the most effective and cost-effective strategy for smokers to reduce their risk of smoking-related disease and premature death. Providing effective, efficient, safe, and patient-centred tobacco cessation treatment to reach those who need them is a significant challenge. To date, only a few nationwide studies in China have assessed the overall clinical care practice and treatment outcome of tobacco cessation. Methods This a prospective, nationwide, multicenter, cohort study covering all Eastern China, Northwest China, Central China, North China, Southwest China, Northeast China, and South China. Participants who were current smokers aged 18-85 years attending clinic for smoking cessation were included. All the participants were treated with 3-month cessation treatment and followed up for 3 months. Data were collected prospectively using online system. The primary outcome was 7-day point abstinence rate at 24 weeks, validated biochemically by an expired carbon monoxide level of less than 10 ppm. The participants lost to follow-up or not providing validation were included as non-abstainers. Findings A representative sample of 3557 participants were recruited and 2943 participants were included into this analysis. These participants had mean age of 53.05 years, and 94.8% were males, with 75.8% showing symptoms of tobacco dependence. A total of 965 (32.8%) participants were treated with Bupropion + behavioural counselling, followed by 935 (31.8%) with behavioural counselling, 778 (26.4%) with Varenicline + behavioural counselling, 135 (4.6%) with alternative treatments + behavioural counselling, and 130 (4.4%) with nicotine replacement therapy (NRT) + behavioural counselling. After 3-month treatment and 3-month follow-up, 21.74% of the participants quit smoking at 24 weeks. In the multivariable-adjusted analyses, quitting smoking was significantly associated with female, higher socioeconomic status, poor health condition, different treatment received, and less smoking intensity. The tobacco cessation treatment varied widely across different areas of China. In particular, the areas with higher usage of cessation medication were associated with better cessation treatment outcome. Interpretation The CNTCCS is the first large-scale nationwide cohort study of smoking cessation in China. Rich data collected from this prospective cohort study provided the opportunity to evaluate the clinical practice of tobacco cessation treatment in China. Funding Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine (CAMS 2021-I2M-1-010), Heilongjiang Provincial Science and Technology Key Program (2022ZXJ03C02), and National Key R&D Program of China (grant no. 2017YFC1309400). Copyright (c) 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:13
相关论文
共 30 条
  • [1] [Anonymous], 2019, WHO REPORT GLOBAL TO
  • [2] Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial
    Anthenelli, Robert M.
    Benowitz, Neal L.
    West, Robert
    St Aubin, Lisa
    McRae, Thomas
    Lawrence, David
    Ascher, John
    Russ, Cristina
    Krishen, Alok
    Evins, A. Eden
    [J]. LANCET, 2016, 387 (10037) : 2507 - 2520
  • [3] Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation A Randomized Clinical Trial
    Baker, Timothy B.
    Piper, Megan E.
    Smith, Stevens S.
    Bolt, Daniel M.
    Stein, James H.
    Fiore, Michael C.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (15): : 1485 - 1493
  • [4] Nicotine Addiction
    Benowitz, Neal L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24) : 2295 - 2303
  • [5] Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006103.pub6, 10.1002/14651858.CD009329.pub2]
  • [6] Contrasting male and female trends in tobacco-attributed mortality in China: evidence from successive nationwide prospective cohort studies
    Chen, Zhengming
    Peto, Richard
    Zhou, Maigeng
    Iona, Andri
    Smith, Margaret
    Yang, Ling
    Guo, Yu
    Chen, Yiping
    Bian, Zheng
    Lancaster, Garry
    Sherliker, Paul
    Pang, Shutao
    Wang, Hao
    Su, Hua
    Wu, Ming
    Wu, Xianping
    Chen, Junshi
    Collins, Rory
    Li, Liming
    [J]. LANCET, 2015, 386 (10002) : 1447 - 1456
  • [7] China National Health and Family Planning Commission, 2015, China clinical guidelines for tobacco cessation
  • [8] "Hardcore" definitions and their application to a population-based sample of smokers
    Costa, Michelle L.
    Cohen, Joanna E.
    Chaiton, Michael O.
    Ip, David
    McDonald, Paul
    Ferrence, Roberta
    [J]. NICOTINE & TOBACCO RESEARCH, 2010, 12 (08) : 860 - 864
  • [9] Mortality in relation to smoking: 50 years' observations on male British doctors
    Doll, R
    Peto, R
    Boreham, J
    Sutherland, I
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7455): : 1519 - 1528
  • [10] FAGERSTROM K O, 1990, Ear Nose and Throat Journal, V69, P763